Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/83770
Corporate Capabilities ADVERTORIAL Baxter B Industry Leader with Global Presence axter has more than 80 years of par- enteral contract manufacturing expe- rience with over 50 manufacturing facilities across six continents. Bax- ter's global presence provides opportunities for unique manufacturing collaborations to provide the most value for our partners. The power of an extensive global network lies in the coordination of, and efficiencies resulting from, a systemic ap- proach to cGMP manufacturing. BioPharma Solutions, a business unit of Bax- ter, works with pharmaceutical companies to support their commercialization objectives by providing sterile manufacturing solutions, par- enteral delivery systems, and customized sup- port services needed to meet the unique chal- lenges that parenteral products face. BioPharma Solutions is a leading contract manufacturer of prefilled syringes in North America and has more than 25 years of success- ful collaborations working with pharmaceutical companies in developing and launching their product. BioPharma Solutions was recognized for the "Most Effective Scale-up/Technical Transfer" at the European Outsourcing Awards and the "Best Contract Manufacturing Orga- nization" at the Vaccine Industry Excellence Awards, three years in a row. Meeting Parenteral Manufacturing Challenges Parenteral manufacturing can be a complex process. Cytotoxics, antibody-drug conjugates (ADCs), highly potent compounds, biologics, and lyophilized products require specialized un- derstanding. BioPharma Solutions offers a dedi- cated facility that utilizes experienced operators, sophisticated equipment and systems, robust standard operating procedures, training, and risk assessments. Our contract manu- facturing services provide customers access to world-class scientific expertise, state-of- the-art facilities, and processes designed to help ensure a reliable supply of quality product to the market. The Bridge to Certification Baxter Healthcare One Baxter Parkway Deerfield, IL 60015 Phone United States 800.422.9837 International 847.948.4779 Website www.baxterbiopharma solutions.com Date Founded 1931 Number of Employees 49,700 Baxter's facilities in Germany have been recognized and certified for their ca- pabilities in handling potent pharmaceu- tical compounds by SafeBridge Consul- tants, a leading occupational health and safety consulting firm. Baxter is the only company worldwide with facilities certi- fied by SafeBridge doing both parenteral drug substance synthesis and parenteral drug product manufacturing and testing. We Take Partnering Seriously As a partner to over 60 pharmaceutical cli- ents, we realize that successful alliances are criti- cal in this extremely competitive environment. BioPharma Solutions has developed strong orga- nizational capabilities to ensure our partnership provides the value you deserve and expect. Ultimately, our goal is to make you feel con- fident and secure choosing BioPharma Solutions as a partner—helping you to avoid the unex- pected and guiding you through marketplace complexities so you can achieve the full po- tential of your molecule. BioPharma Solutions provides our clients with confidence of delivery, service, and integrity—we know the work we do is ultimately vital to the patients you serve. Areas of Expertise As a parenterals specialist, BioPharma Solu- tions offers unique delivery systems and a vari- ety of manufacturing solutions to meet complex and traditional manufacturing challenges. Areas of expertise include: Sterile Manufacturing Solutions UÊ Prefilled Syringes UÊ Liquid Vials UÊ Lyophilized Vials UÊ Cartridges UÊ UÊ Ampoules UÊ Powder-Filled Vials UÊ Sterile Crystallization Parenteral Delivery Systems UÊ Frozen Premix System UÊ Liquid Premix System UÊ BIO-SET Luer System Drug Categories UÊ Small Molecules UÊ Biologics UÊ Vaccines UÊ Cytotoxics UÊ Antibody-Drug Conjugates (ADCs) UÊ Highly Potent Compounds UÊ Cephalosporins / Penicillins Diluents for Reconstitution 66 | October 1, 2012 | genengnews.com | Genetic Engineering & Biotechnology News